REYKJAVIK, ICELAND (June 26, 2025) - Alvotech SA (NASDAQ: ALVO, ALVO SDB), a global biotech company known for developing and manufacturing biosimilar medicines, has announced a reduction in the interest rate on its senior secured term loan facility. This agreement, made with its lenders, including GoldenTree Asset Management, will decrease Alvotech's interest payments by an estimated $8.2 million over the next year. The facility, originally consisting of two tranches totaling $965 million, has been restructured into a single tranche with a lower interest rate of SOFR plus 6.0% per annum. The move reflects Alvotech's improved financial performance and investor confidence in its future growth and product launches. As of June 25, 2025, the facility's balance stands at approximately $1,081 million, with a cash balance of around $152 million.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。